| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
(S)-6-(3-(tert-Butyl)-5-(3-(2,3-dichlorophenyl)ureido)-1H-pyrazol-1-yl)-1,2,3,4-tetrahydroisoq manufacturers
- BCR-ABL-IN-2
-
- $8630.00
-
2026-07-27
- CAS:897369-18-5
- Purity:
- Supply Ability: 10g
- BCR-ABL-IN-2
-
- $2380.00
-
2026-05-21
- CAS:897369-18-5
- Purity:
- Supply Ability: 10g
- BCR-ABL-IN-2
-
- $3180.00
-
2025-04-30
- CAS:897369-18-5
- Purity:
- Supply Ability: 10g
|
| | (S)-6-(3-(tert-Butyl)-5-(3-(2,3-dichlorophenyl)ureido)-1H-pyrazol-1-yl)-1,2,3,4-tetrahydroisoq Basic information |
| Product Name: | (S)-6-(3-(tert-Butyl)-5-(3-(2,3-dichlorophenyl)ureido)-1H-pyrazol-1-yl)-1,2,3,4-tetrahydroisoq | | Synonyms: | (S)-6-(3-(tert-Butyl)-5-(3-(2,3-dichlorophenyl)ureido)-1H-pyrazol-1-yl)-1,2,3,4-tetrahydroisoq;BCR-ABL-IN-2;3-Isoquinolinecarboxylic acid, 6-[5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]-1,2,3,4-tetrahydro-, (3S)-;BCR ABL IN 2,BCRABLIN2 | | CAS: | 897369-18-5 | | MF: | C24H25Cl2N5O3 | | MW: | 502.39 | | EINECS: | | | Product Categories: | | | Mol File: | 897369-18-5.mol |  |
| | (S)-6-(3-(tert-Butyl)-5-(3-(2,3-dichlorophenyl)ureido)-1H-pyrazol-1-yl)-1,2,3,4-tetrahydroisoq Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | (S)-6-(3-(tert-Butyl)-5-(3-(2,3-dichlorophenyl)ureido)-1H-pyrazol-1-yl)-1,2,3,4-tetrahydroisoq Usage And Synthesis |
| Uses | BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively. | | Definition | ChEBI: DP-987 is a member of the class of phenylureas that is urea in which one of the nitrogens bears a 3-tert-butyl-1-[(3S)-3-carboxy-1,2,3,4-tetrahydroisoquinolin-6-yl]-1H-pyrazol-5-yl substituent, while the other bears a 2,3-dichlorophenyl group. It is a member of pyrazoles, a member of isoquinolines, a non-proteinogenic L-alpha-amino acid, a dichlorobenzene and a member of phenylureas. | | References | [1] Chan WW, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011 Apr 12;19(4):556-68. DOI:10.1016/j.ccr.2011.03.003
[2] ARYL SULFONOHYDRAZIDES. US 2008/0113967 A1. |
| | (S)-6-(3-(tert-Butyl)-5-(3-(2,3-dichlorophenyl)ureido)-1H-pyrazol-1-yl)-1,2,3,4-tetrahydroisoq Preparation Products And Raw materials |
|